Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UBX domain containing 2 pseudogene (ENSG00000232009) is annotated as a pseudogene, meaning it closely resembles a protein-coding gene (such as UBXN2A or UBXN2B, both real family members) but contains mutations that prevent production of a functional protein. Pseudogenes generally do not play direct roles in biology or disease and are not considered therapeutic targets. The active, protein-coding family members UBXN2A and UBXN2B participate in ubiquitin-proteasome regulation and cellular protein homeostasis, but the pseudogene ENSG00000232009 does not share their functions[6][5][2]. There is nothing to suggest this entry refers to an actual receptor, enzyme, transporter, or other druggable protein. If you are seeking biological or therapeutic context, refer instead to closely related protein-coding genes such as UBXN2A or UBXN2B[6][5][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UBX domain containing 2 pseudogene (ENSG00000232009).